LAS VEGAS — Etanercept was effective for the inhibition of bone marrow lesions in patients with erosive hand osteoarthritis, according to a presenter here at the Osteoarthritis Research Society International World Congress.
“We saw a pronounced beneficial effect of etanercept on bone marrow lesions in joint with synovitis at baseline,” Féline P. Kroon, from Leiden University Medical Center in the Netherlands, said in her presentation. “This could mean there is an interaction between the synovium and the subchondral bone which could be influenced by tumor necrosis factor-alpha.”
Féline P. Kroon
Kroon and colleagues identified 20 patients from a double-blind trial of etanercept who had symptomatic, erosive hand osteoarthritis (OA). Patients had inflammation in at least one inter-phalangeal joint and underwent MRI of these joints at baseline and at 1 year.
Between baseline and 1 year, researchers found comparable total synovitis scores for both placebo (10.5 and 10.3, respectively) and etanercept (7 and 6.9, respectively) groups. However, for bone marrow lesions, total score increased for placebo (5.4 and 7, respectively), but decreased for etanercept (4.5 and 3.7, respectively).
Furthermore, etanercept was linked with a reduction in bone marrow lesions (beta = –0.22). In addition, bone marrow lesions were linked with the erosion phase (ratio = 12.5) and the remodeling phase (ratio = 3.9); whereas, synovitis was not linked with either phase. – Will A. Offit
Kroon FP, et al. Paper #49. Presented at: Osteoarthritis Research Society International World Congress; April 27-30, 2017; Las Vegas.
Disclosure: Kroon reports no relevant financial disclosures.